Form 8-K - Current report:
SEC Accession No. 0001104659-22-022829
Filing Date
2022-02-14
Accepted
2022-02-14 16:15:33
Documents
15
Period of Report
2022-02-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm226582d1_8k.htm   iXBRL 8-K 26713
2 EXHIBIT 99.1 tm226582d1_ex99-1.htm EX-99.1 43387
7 GRAPHIC tm226582d1_ex99-1img001.jpg GRAPHIC 4997
  Complete submission text file 0001104659-22-022829.txt   308956

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA otlk-20220214.xsd EX-101.SCH 3560
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE otlk-20220214_def.xml EX-101.DEF 27168
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20220214_lab.xml EX-101.LAB 37126
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20220214_pre.xml EX-101.PRE 25790
9 EXTRACTED XBRL INSTANCE DOCUMENT tm226582d1_8k_htm.xml XML 5309
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 22632139
SIC: 2836 Biological Products, (No Diagnostic Substances)